-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KQwUZNmI9imJSQSpFkxPwumb2Y7edNPTko1xEjvNaX4I7eYNT4z0aLciMnFX564P
 n6zRo0U1FbIAoUmOx1VRxg==

<SEC-DOCUMENT>0001019687-10-001108.txt : 20100324
<SEC-HEADER>0001019687-10-001108.hdr.sgml : 20100324
<ACCEPTANCE-DATETIME>20100324171542
ACCESSION NUMBER:		0001019687-10-001108
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100324
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100324
DATE AS OF CHANGE:		20100324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		10702472

	BUSINESS ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE #660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE #660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k-032410.htm
<DESCRIPTION>AETHLON 8-K
<TEXT>
<html>
<head>
    <title>aethlon_8k-032410.htm</title>
<!-- Licensed to: publicease-->
<!-- Document Created using EDGARizerAgent 5.1.6.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 1pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">FORM 8-K</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Date of Report (Date of earliest event reported): March 24, 2010</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 24pt; FONT-WEIGHT: bold">AETHLON MEDICAL, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td valign="center" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="center" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="center" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="center" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="center" width="25%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nevada</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">000-21846</font></div>
</td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">13-3632859</font></div>
</td>
</tr><tr>
<td valign="top" width="25%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other Jurisdiction of Incorporation)</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File Number)</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td valign="center" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="center" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="center" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">8910 University Center Lane, Suite 660</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">San Diego, California</font></div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">92122</font></div>
</td>
</tr><tr>
<td valign="top" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of Principal Executive Offices)</font></div>
</td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code: <font style="DISPLAY: inline; FONT-WEIGHT: bold">(858) 459-7800</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td valign="center" width="55%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Not applicable&#160;</font></div>
</td>
</tr><tr>
<td valign="center" width="55%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Former name or former address if changed since last report.)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font>&#160; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font>&#160; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font>&#160; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline;" face="Wingdings">o</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 7.01 Regulation FD Disclosure</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 24, 2010 following the close of market, the Company&#8217;s&#160;&#160;Chief Executive Officer disclosed&#160;&#160;certain material information&#160;&#160;at an investor conference that had not been previously disclosed to the public.&#160;&#160;The attached press release (the "Press Release")&#160;summarizes certain of the information disclosed at the investor conference&#160;and is filed as Exhibit 99.1 to this Form 8-K.&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In accordance with General Instruction B.2 of Form 8-K, the Press Release&#160;shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall the Press Release be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Item&#160;9.01 Financial Statements and Exhibits</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(a)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="67%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">None.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(b)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="67%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">None.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(c)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="67%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">None.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(d)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="67%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exhibits</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="9%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exhibit&#160;No.</font></font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="60%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="9%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="60%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release dated March 24, 2004</font></div>
</td>
</tr><tr>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURES</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">AETHLON MEDICAL, INC.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="17%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="17%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 24, 2010</font></div>
</td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline">/s/ James A. Joyce<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="17%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date</font></div>
</td>
<td align="left" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">James A. Joyce, Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>aethlon_8k-9901.htm</title>
<!-- Licensed to: publicease-->
<!-- Document Created using EDGARizerAgent 5.1.6.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div>Exhibit 99.1</div>

<div>&#160;</div>

<div>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><img src="aethlon_8k-99010.jpg" alt=""></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Aethlon Medical Regulation FD Disclosures</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Proposed Strategic Arrangement with Membrana GmbH</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Initiates New Breast Cancer and Lymphoma Research Collaborations</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Discloses First Bacterial Infection Data (Tuberculosis)</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Initiates First Compassionate Use Treatment in Cancer Care</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Completes First Hemopurifier<font style="DISPLAY: inline;" face="Symbol, serif">&#210;</font> GMP Production Run</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Discloses India Commercialization Update</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">San Diego, March 24, 2010 &#8211; At an investor conference held today, following the market close, Aethlon Medical, the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed the following:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Proposed Strategic Arrangement with Membrana GmbH</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has signed a letter of intent with Membrana GmbH (Membrana) in an effort to establish a manufacturing arrangement to support large-scale production. Membrana is a leading independent membrane producer worldwide, and is the manufacturer of the hollow-fiber membranes currently utilized in the Aethlon Hemopurifier&#174;. &#160;Membrana is also a leading supplier of microporous membranes for medical applications like dialysis, and plasma separation. Membrana GmbH is a subsidiary of Polypore International, Inc. &#160;The arrangement is subject to completion of a definitive agreement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Initiates New Cancer Research Collaborations</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Aethlon has also initiated two research studies aimed at determining the capability of the Hemopurifier<font style="DISPLAY: inline;" face="Symbol, serif">&#210;</font> to capture immunosuppressive exosomes associated with breast cancer and lymphoma.&#160;&#160;The details of the studies are as follows:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An <font style="FONT-STYLE: italic; DISPLAY: inline">in vitro</font> study, under the collaboration of Douglas D. Taylor, Ph.D., Professor of Obstrectics, Gynecology, and Women&#8217;s Health at the University of Louisville, has been initiated to determine the capability of the Hemopurifier&#174; to capture immunosuppressive exosomes associated with breast cancer.&#160;&#160;Dr. Taylor previously conducted studies that validated the Hemopurifier&#174; was effective in capturing immunosuppressive exosomes associated with ovarian cancer.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An <font style="FONT-STYLE: italic; DISPLAY: inline">in vitro</font> study, under the collaboration of Andrew Raubitschek, M.D., Chair of the Department of Cancer Immunotherapeutics &amp; Tumor Immunology at the Beckman Research Institute of City of Hope in California, has been initiated to determine the capability of the Hemopurifier<font style="DISPLAY: inline;" face="Symbol, serif">&#210;</font> to capture lymphoma related exosomes.&#160;&#160;Dr. Raubitschek is also Co-leader for the Cancer Immunotherapeutics Program at the Comprehensive Cancer Center and Chief of Radioimmunotherapy and Professor, Radiation Oncology also at the City of Hope.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Disclosure of First Bacterial Infection Data</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">An <font style="FONT-STYLE: italic; DISPLAY: inline">in vitro</font> bacteriological study, under the collaboration of Jeffrey Schorey, Ph.D., of the Eck Institute of Global Health at the University of Notre Dame, demonstrated that the Hemopurifier<font style="DISPLAY: inline;" face="Symbol, serif">&#210;</font>, in a 4-hour period, captured 97% of exosomes secreted by <font style="FONT-STYLE: italic; DISPLAY: inline">mycobacterium tuberculosis</font>, the pathogenic bacterial agent that causes Tuberculosis.&#160;&#160;Dr. Schorey is a 2009 recipient of a Bill and Melinda Gates Foundation grant to study exosomes as a potential Tuberculosis vaccine.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Disclosure of First Compassionate Use Treatment</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company also revealed the completion of its first compassionate use treatments of the Hemopurifier&#174; on an end-stage lung cancer patient.&#160;&#160;The treatments were conducted at the Netcare Christiaan Barnard Memorial Hospital in Cape Town, South Africa and had clinical support from National Renal Care, a leading kidney disease management organization in South Africa.&#160;&#160;The Company is currently testing the Hemopurifier<font style="DISPLAY: inline;" face="Symbol, serif">&#210;</font> cartridges used in the treatments to determine the capture rate of immunosuppressive exosomes secreted by lung cancer.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Completion of First GMP Production Run and India Commercialization Update</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has completed the first production run of approximately 100 Hemopurifier&#174; cartridges under good manufacturing practices (GMP) required to export the technology for sale in India.&#160;&#160;Furthermore, the Company has received confirmation from the office of the Drug Controller General of India (DCGI) that under current device regulations the Hemopurifier&#174; does not fall under the list of restricted devices for import or devices that need approval for import.&#160;&#160;As such, the Company is working with Vijay Kher, M.D. to establish HCV-treatment protocols.&#160;&#160;Dr. Kher previously served as the principal investigator of Hemopurifier&#174; human studies to treat HCV at the Apollo and Fortis Hospital in Delhi, India.&#160;&#160;Dr. Kher is presently the chairman of the Department of Nephrol
ogy at the Medanta Kidney &amp; Urology Institute at Medanta &#8211; The Medicity Institute, a $360 million, medical multi-specialty institute established to be a premier center for medical tourism on a 43-acre campus with over 1,600 hospital beds.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">"Our disclosures today support our belief that we can establish and lead the industry for therapeutic devices to treat infectious disease and cancer," stated James A. Joyce, Chairman and Chief Executive Officer of Aethlon Medical, Inc.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Aethlon Medical</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Aethlon Medical, Inc. creates diagnostic and therapeutic device solutions for infectious disease and cancer.&#160;&#160;Our lead product, the Hemopurifier&#174; is the first-in-class medical device to selectively capture circulating viruses and immunosuppressive proteins prior to cell and organ infection.&#160;&#160;Human studies have documented the ability of our Hemopurifier&#174; to reduce viral load in patients infected with Hepatitis-C virus (HCV) and the Human Immunodeficiency Virus (HIV).&#160;&#160;Our primary clinical and commercialization focus is to establish the Hemopurifier&#174; as an adjunct therapy to enhance and prolong the benefit of traditional infectious disease drug regimens.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Hemopurifier&#174; is also a broad-spectrum treatment candidate against drug resistant bioterror and pandemic threats. Third party research institutes have verified the capability of the device to capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) was formed in October of 2009 to leverage attributes of the Hemopurifier&#174; in the emerging exosome research field.&#160;&#160;ESI seeks to inhibit the immune cell destruction caused by exosomes secreted by solid tumors, lymphomas, and leukemia.&#160;&#160;At present, the capture of immunosuppressive exosomes secreted from ovarian cancer tumors has been demonstrated <font style="FONT-STYLE: italic; DISPLAY: inline">in vitro</font>. The preservation of anti-cancer immune cells would likely improve patient responsiveness to established treatment options, including immunotherapy and chemotherapy.&#160;&#160;ESI is also analyzing exosome-related opportunities to improve early cancer detection and post-surgery surveillance of tumor growth, as well as approaches to 
harvest exosomes for research purposes and potential reintroduction into patients afflicted with autoimmune conditions such as Rheumatoid Arthritis and Lupus.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at <font style="DISPLAY: inline; FONT-WEIGHT: bold">www.aethlonmedical.com</font>.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.&#160;&#160;Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier&#174; to reduce viral loads and other disease conditions or to identify disease conditions such as</font> <font style="FONT-STYLE: italic; DISPLAY: inline">cancer, including the ability to capture exosomes and the impact that potential ab
ility may have on disease conditions, the Company&#8217;s ability to raise capital when needed, the Company&#8217;s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company&#8217;s ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company&#8217;s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company&#8217;s Securities and Exchange Commission filings.</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contacts:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">James A. Joyce</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chairman, CEO</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">858.459.7800 x301</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #0000ff; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jj@aethlonmedical.com</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">John P. Salvador</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Director of Corporate Communications</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">858.459.7800 x307</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; COLOR: #0000ff; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jps@aethlonmedical.com</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>aethlon_8k-99010.jpg
<TEXT>
begin 644 aethlon_8k-99010.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`%@`
MZP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`*"0.IQ7EO[5G[7'P8_8Y^&DOQ.^,VO_`&:U),=A8P8>ZU"?&1##'D;F
M]3PJC+,0`37XM?MK_P#!7C]IK]K?4+SPWH.NS>"_!;L4@\/:)<LDMQ%T'VJ=
M</+D=4&U.VT]3]GPGP+GG%U3FP\>2DG9U):1]%_,_)'S>><49;D:Y:CYI](K
M?Y]$C]?OC?\`\%)_V*?V>+V72?B=\>M&@U"`E9M+TYWOKJ-A_"\5LKM&?]_;
M7@6O?\'"G[#&D7GV73_#'Q"U-03F:RT*U11^$UTC?I7XHDDDDG)/>BOW'+_`
MWAO#P7UJM4J2ZM-07W)/\V?G&)\0LXJ2_<PC%>E_U1^WGA#_`(+_`/[!GB6=
M(=93QGH"N^#+JOA]'51ZG[+-*V/H#7TK\#_VR/V8?VD80WP5^-&@Z_,$WO8V
MMX$NHU]6MY`LJ]^JCH:_FNJQI6K:IH6HPZOHNHSVEW;2"2WNK65HY8G!R&5E
M(*D'N.:PS3P,R*I3<L!7G3GTYFI1_)/\2\+XB9K2E^_IQDO+W7]^I_4Y]**_
M%S]@[_@N=\6_A%J-KX!_:PNKGQAX8=EB7Q%C=JFG+G&YS_R](.2=W[SN&;`6
MOU_^&?Q+\%_%_P`%V'Q$^'GB&TU;1=5MUFT_4+*8/',A]^Q'0@\@@@X(K\(X
MHX1SKA+$JGC8>Z_AFM8R^?1^3L?IN2Y_E^>T>:A+WEO%[K_,Z2BBBOF3VPHH
MHH`****`"BBB@`HHKC_C[\>?A=^S'\(=>^/'QK\3+HWA7PQ8->ZYJC6\LPMH
M`0"^R)6=N6'"J3[4`=A17F/[)/[8G[/'[<WP@B^/'[,'Q`3Q-X5GOY[*+5$L
M+BV#3PD"1-EQ&C\$XSMP>Q->G4`%%%>!_L]_\%-OV+?VIOVA/&/[+'P+^,*:
MYX[\`27B>+M"32+R$V!M;L6D^9)85CDVSD)\C-G.1D<T`>^4444`%%%%`!11
M10`5Q?QT^,W@?]GCX5ZU\8/B+J0M-&T*Q>YO),C<V,!(T!^\[,515[LP%=I7
MY(?\'#G[5-WJ7BOP]^R'X8U$K:6$":WXI6-_]9<2;EMH6Q_<0-(1T)EC/517
MTG"/#M7BCB"C@(Z1;O)]HK63^[1>;1XO$&;1R;*JF)^TM(KNWHCXD_;/_;!^
M)G[:?QGO?BI\0+N2&V#M#H.B)*3#I=IGY8D'=B,%WP-S9/`P!Y+1WK]'O^"3
M7_!(3X=_M(?"N7]H+]J'3M0FTC596B\*Z%;7CVWG0KE6NY'0A\%@5100"%+'
M((K^OLUS;(?#_(8.HN6C"T8QCJV^R3:]6_(_",#@<RXCS)QA[TY7;;V^9^<-
M%?O%_P`.,/\`@G'_`-$AU/\`\*R__P#CU-_X<6_\$X\_\DBU3_PJ[_\`^.U\
M1_Q''A/_`)]5O_`8_P#R9]+_`,0\SO\`FA][_P`C\'Z*_0;]OG]A+]@/3/$/
MBSX/?L6_%""#XP?#GP\FO^*_A?)J\]U<3:2RJS2IYP)$J1NLIC1V.QE)1?,0
MG\^:^_X8XMRKB[!2Q&";7*[2C+22>ZNE=6:VU/E\VR?&Y+B?8XE;ZIK5/^F%
M?7O_``2@_P""C.L_L>_%*+X=_$+5Y9OAQXFO%CU:"1R1I,[85;V,?PJ.!(HZ
MKR`2H!^0J*[,[R+`Y_EE3!8N-XR7S3Z->:>QAE^/Q.68N&(H.SB_O\GY']3U
MC?VNI6Z7=E.DL4L:O%+&X974C(8$=0?6IJ^'?^"%7[55[\>_V3C\-/%&H_:=
M=^'=Q'IKR229>73V#&T<_P"ZJO#](`3UK[BK^&\XRS$Y+FM;`5U[U.37KV?H
MUJ?T;EN/I9G@88FGM)7]'U7R9G>+/%&C>"?#6H>+O$=XMMI^EV,UY?W+YQ%#
M$A=W.`20%4GCGBOSBNO^#IK]@OQ-JL^C_L\?`KXZ?%5H03]J\$?#>26!POWR
M/-D23Y>IS&!R*_2#Q+X<TCQ;H5YX9\0Z=!>:?J%I);7UG=1"2.>&12KQNIX9
M64D$'@@U\X?&#_@H[_P2\_X)Z:$/`/Q._:*^&W@*/2HA'#X1TBYA-U;JHP$6
MPLU:1<<#`C&`1VKS3M=^AXC^S?\`\'+W_!.WX^?&C3_V=_%UCX[^%OC'5+R*
MST_3/B=X:_L])[J1MJ0^:CR+&Q;"CS=@+$`$DXK[>^,'QA^&WP)\#7GQ)^*_
MC&RT/1=/CW7-]>OA0>R@<EF)X"J"2>`#7\R?_!RA_P`%/?@O_P`%*]8^&WCK
M]F3X'^(K/PQX.N=0LT^*^M^'Y+$ZY<3"&1;2V8\M'"(C+ASO#2YV1C)D_2;_
M`(+`_'/PYXV_;4^%?[/GQAUC41\//#VG6.K^*[73X9));R2=F>7Y$Y<^1&B*
M1ROFR8QSGW^&<C_U@S:.&DVH*,IR:5WRP5WRK^9[+U/&SK-'E.!]M%7DVHJ^
MUV]WY)79]/6__!;G]G#5X9]9\(?!KXK^(-#LV*W'B/2/!9>T4#JQ)D!`'^U@
M^U>K^$O^"DO[)_CS]G'QG^U'X-\>MJ/AOX?^&K[7/%UK!:L+_3[:TMI+F4-;
MMABWEQ/M_A8@X)KR3PG_`,%CO^">O@;P]:^%/"ECXHL--LK=8+2QL_`5Q%%#
M&HP%50H``%?*?[,/Q4^'/B+_`(+2VWBS]F'0=3MO`'Q!M+FUUW3;S17M896>
MPDDF#1.N`IN(DEYXRS`8!Q7TM3AC#XS"8EQPE3#.E"4XN<N93Y;7BURJS:U5
MM--CPXY]5P^)HIXB%93DHM1C9QOU5F]$^_WGR!X2_P"#CKP*W_!<O6OVI/&O
M[0/Q0N/V:H],DB\-^#RDS16LSZ/!;[QIXE"*3=+.^[D_/NK[V_;@_P""I/[*
MW_!4C_@A]^U)X^_98O==GT_PMX3-AJIU[2#9NLTABD7:I9MPV]_6OF3X*^%?
M#$G_``>B?$;PY)X;L&T]/#K;;$V:&$'_`(16P/"8VCDD].M?HY_P7?\`#GA[
MPY_P1M_:%A\/:#96"2>`9FD2RM4B#D2Q8)"@9-?G9]I$^!/^"#?_``53_8N_
MX)C_`/!$;PSXG_:K^)O]GW6K>//$+:)X<TNW-UJ>I;)H\F*!2,*.AD<H@/!;
M.!7M/AG_`(/$?^"7FJ^*HM"\5>`?BOX=LIY%$6KZEX8MGB5&/$CI#<O(%Q@_
M*K'G@&O`/^#17_@FE\%?B+^SQK'[>GQT\#Z?XGUZ/Q7/H7P]@UZV6Z@T2TMA
M'+-<V\<F52:6XFD7=C<HA.TCS'S^FG_!6S]B3]G']J7]@CXG>%_B;\+=#GET
MCP'JVI:!JJZ7&MUI5];6DDT%Q!*H#1E7C7*@X==R,"K$4#:N>^_`WXZ?"G]I
M+X7Z1\:?@AXWL/$?A;7K07.CZUIDV^&YC)*D@X!!#*RLIPRLI5@""!^'W_!O
M`?\`CHG_`&U_^PCXP_\`4MCKVC_@RV\<^(=?_P""<GQ`\&ZKJ$L]GH/Q<N/[
M+260MY$<^G6,CQH#]U?,#O@?Q2.>]>+_`/!N_P#\K$_[:_\`V$?&'_J6QT"D
M?LQ^V#^VU^S-^P;\*9/C/^U+\5-/\+:$)3#;273,\U[/M+""WA0-)/(0"=J*
M3@9.`"1^?5]_P=_?\$WX;N2^TWX*?&J^T"*0H_B.#PC:BWSDC(#78.#@?>P>
M>0#Q7R]\;/#T'_!9'_@Z%E_91^.376J_";X&V%P3X8>8^1<QV<$,EQO"M@>?
MJ$\22-]YX8TC)&!M_=C2/A'\-=`\%Q_#?0_`&AV?AZ&V%O%H5KI,,=FL0&!&
M(54(%`XQC&*`W/*_V(/^"E'['G_!1/P#/\0/V3_BW9^(H[%E35M*D5K>_P!-
M9L[1<6T@$D8;!"MC:V#M)P:YO]N/_@K7^R7_`,$]OBC\/?@_^T-=>((]:^)M
MR\'A=-&T<W4;.L\,!\U]P\OY[B/UXR>U?D?^V3\/O"?_``1!_P"#C?X,?%3]
MFBW@\,?#SXVFRM?%?ABP/DV%M#>ZA]AOXUB7@0H?L]ZB#`64%5PJ@4__`(/1
M5\33?M%_LS6O@J2XCUB73M9727M)"DHNC=Z>(MC`C:V_;@]CCI0-NQ]]_MC_
M`/!S=_P3/_8[^*%]\%+S7/$WC[Q3I-R]OK%A\/M)2\AL)T.'ADN)9(HVD7D,
ML9?805;:014G[$O_``<T_P#!,K]M[XI:7\$/#?B7Q)X+\5ZW<);Z-IWCK2H[
M6'4+A^%@BN(I98O,)P%61D+L0J[F(!]U_P""=G_!,G]FG_@GS^SYHOP=^&OP
MWT235[?3H?\`A*/%4VFQO>ZYJ&S]_<S3,-[;G+%5)VHI"J`!7Y&_\'C_`.R7
M\%/@C9_!_P#:W^$O@RP\,^--6\27NF:QJ/AZT2S-^(H8I[>>3RP,S1,C!9/O
M8?!)VK@&?T#DX!-?S=_M_P#Q,NOB_P#MJ?$SQ[<7!ECG\77=M9MNS_HULYMH
M<>WEQ)7]"?P$\6ZMX_\`@3X.\>:\ZM?:WX1TZ_O3&,+YLULDCX'8;F-?S4_%
M'SQ\3_$OVD'S/^$@O/-R,'?YS;OUS7[IX&4*;S;%UWO&"7R<M?R/S+Q+JR6#
MP]);.3?W6_S.W_8L_9A\0_M??M'^'/@CHHDCMKZZ\[7+U%_X\["/#32Y[';\
MJYZNZCO7]&W@CP7X>^'OA33O!'A/38;/2])L8;/3K2!,+!#$@1$'L%`%?$W_
M``0N_8O7X$_L^/\`'KQCH_E>*/B!''/;B>/#VNE#YK=!GH9?]:WJ#&#]VOO.
MOE_%3BE<1\0NA1E>C0O%=G+[3^_1>AZ_`^2?V9EGMJB]^K9ONET7ZA7B?_!0
M[]LKX?\`[`'[(?C/]K#XC-'):^%=)DET_3GEVMJ5^_[NUM$/K+,T:$C.U2S'
MA37ME?S+_P#!W1_P4T?X^?M*Z?\`L"_#/6_-\)_"^X%YXI>"0[+SQ#)$1LR.
M&%M#)L]I)IU(R@K\S/MC\[/A=_P49_:&^&_[>MK_`,%$I-=_M+QZ/&C^(-5F
MN&*QZ@)787-FX'2"6%W@*#@1O@8P,?IA^UGX"^']AXBT/X\_`?,OPQ^+&BIX
MH\!3<?Z-#,?](T]\<++:S[X'3)*[5R>:_%+ZU^HG_!%KXW0_M2_`;Q;_`,$N
M_&%T9?$%E)<>,?@-),PW#48HF?4M'0GG%S;QF9$R%\V%V.2V#]_X<<3OAGB&
M,JDK4:MH3[)/:7_;KW_NMGR?&&2_VOE3Y%^\I^]'OYKYHT**62.6*5H9HRC(
M<,K#!4]P1V-(.M?V?2J*4;K8_`]C[I_X-^OB5=^%/VTK_P"'QG(M?%OA*YA,
M/8W%NZ3QN1WPB3#_`('7[=U^`?\`P14$Q_X*7?#CRE;`&K^:1G`7^R+WK[9V
M_CBOW\K^2_&C#4L/QDIP^W3C)^MY1_**/VSP[K2J9#*+^S.27X/\V?FI_P`'
M5G[6/Q]_9)_X)A1:[^SWXMOM!U'QCX_LO#&L:UI4K175GI\UI>W$IBE7F$NU
MK'$7&"%E(!!(KG?^"(7_``0]_P""<7A;]D'X;_M0>+?AIH/Q7\<^-O"-AX@U
M3Q3XMA34X+:YNX%FD@MX)-T2>4SF(LRF4M&Q8@DJ/T#_`&M/V3?@C^VU\#=:
M_9S_`&A_"$6M^%->@"7UFSLDD<BLKQ312*0T4L;J&5QT(QR"0?SV\`?\&O>F
M?`ZSNO!_[.'_``5>_:1\!^$;B:1T\,Z%XH2**/>26P8A&@8\98("3R?;\E/O
M#P#_`(/7M"TKP[^S7\`M(T'3;>RM+?Q?JZV]K:0K''$HM8.%50`!]!7O7_!1
MN&Z_93_X*-?!3]N+6=+GE\*W=A8V6LW20;Q`\2R13KTP";:<,J]6\M\9Q7L7
M[07_``;X_LM_M3?LC?##]D7XX_&OXG:O8?"Z]U"]L?$S:_"^JZM=WLK37,UY
M-<0R^86=V(P!M!`Z`5]>?%S]G_X6?'7X8S_"#XL^$K76]"N841[6[3E2HPLB
MLN&1P>0RD$5[W#F<T\CS/VU6#E3G&4)I:/EFK.WFNAX^=9=4S/!>SINTXM2B
M_.+NK^3-GP1XH\%?$'PY:^,/!FIZ=J>F7\"S6=]8NDD4R,,AE9>"*N#4_#T6
MLIHJ26:7S0-,EL&7S2@(4N%Z[064$]BP'>OB&'_@AC\/O"EQ/:_"']KGXL>#
M]*G<LVDZ7KH$8)/."H7(_P![)KV#]CS_`()K?"S]CGQGJOQ+\/?$'Q3XH\2:
MSIGV&]U;Q3J*SL(?,60A`$!&652<L<[11CL'D%*C*>'QLIR^S%TW%^DGS67J
MDS/"XC-JE6,:V&C%=9<R?W)+]3\J/AQXH\/>$?\`@];\>2>(]7M[,:EI:V5@
M;B0()KB3PE8LD2D\%F"-@=R`!DD"OTD_X+XWMO<_\$>?VA;>.5"\7P^E+H'!
M(S-'C([=#7FO_!2__@W`_9)_X*2?'V+]J/6/B9XM\`>.Y+2W@U76/"CPE-1-
MNJI!-)'*A*S(B(@=6'RQH",J#6]^S9_P0*_9_P#@!^QK\5_V,-7^/GQ$\6Z3
M\8DBC\4Z_K-_;_VA#'$N$2W;RF5`/F/S!^6/K7@GMI6/-/\`@T4_Y0YZ-_V4
M#7?_`$<E?=O[:HS^QM\6^?\`FF.O_P#INGKFO^"=?_!/WX.?\$S_`-F^V_9?
M^!.NZ]J/A^UU>ZU&*X\27<4UUYMPP9P6BBC7:"./ES[FO5/BK\.M(^+?PU\0
M_"[7[B:&P\2:%>:5?26K!9%AN86A<H2"`P5S@D$9['I0/H?D'_P9/_\`)B7Q
M9_[*V/\`TUV=>7?\&\'_`"L3_MK_`/81\8?^I;'7ZJ?\$P/^"5O[/_\`P2?^
M%7B+X0_L\^*/%&J:9XE\0#6+Z7Q3>P3S).((X,(888@%V1KP03G/-<_^QY_P
M1I_9J_8E_;#^)W[;7PH\9>+[OQ7\5YM2D\0VFM7]O)90?;=06_E$"1P(Z8E4
M!=SMA2<Y/-!#3/R\^(/BNS_X)%_\'5>J_'+X[7C:1\-/CG83^1XHN6"VT,.H
M00"1Y&^ZJPZG;(LF2-D3+(<`C/[UZ?XITC5M'C\0Z9?6]Q830">"]@N%>*2,
MC<'#C@J1SG.,5X_^WE_P3L_95_X*0_">+X0?M3_#F+6;"SF>XTC4+>0P7VE7
M#+M,UM.O,9(X*D,C8&Y6P,?G\/\`@TC^#6G:1+\/_#'_``4<^/>G^"9IMTGA
M!-;@-L4Z!"H01M@8&3'ZT%)6/FW_`(**^,O"_P#P6$_X./O@=^SU^SC=P>)/
M"OP;FL6\<:_I_P"\M<6FH&^U/$R_*8U1(;4.#CSV*C.172_\'9Z@_P#!0']C
M`$9!UVXR/^XKI=?J/_P3Q_X)+_L:_P#!,+P=>>&/V7/`#V]_JJ(NN>*M:G^U
M:KJ>W[JRS84!`>1%&J1Y).W/-8G_``4(_P"".W[-O_!2/XN?#3XS?'#Q?XMT
M[5/A9<O/X=B\.7\$,,SM<6\Y\\2PR%AOMT'RE>"?;`+E/K3`'05^(G_![I_R
M:Q\$/^R@:A_Z1"OV[KY;_P""HW_!);]G;_@K/X$\*_#[]HGQ3XJTNR\(ZM/J
M&G/X5OH()))98A$PD,T,H*A1P`!S04>P_LEKG]E;X:CU^'VC?^D,5?D#X(_X
M)VZG\:/^"OGC;X&ZYICIX4\/^,+K7O$,GEE5_LN247,$.?[THFCC&.<%V'W3
M7[3?#CP/IOPT\!:+\/=&GEEL]"TBVTZS>=@7:*")8T+$``MM49P`,]A5;0OA
MIX,\.>,M:^(6D:!:P:UXACMH]7U&./$ETMNK+"&/<(KL!]:^GX<XJQG#%/%?
M5_BK4^1/JG=:KY77S/"SK(Z&<SH.KM3ES/S7;[[/Y&[8:?::9:QV-C;QQ00Q
MK'#%$@5451@*`.``.`*GHHZ5\QN>XDDCP?\`X*$?M8Z5^QM^S)KOQ>GFA?5O
M*^Q>&K)V_P"/G4)01$N.ZK@R-_LQM7\E/_!1SX9:OJ?C*3]H:XNIKNYUZ]=O
M$=S)RTEZ[,_GN>YDYR?5<DDMS^NW_!:[]LIOVD_VF'^%OA'5A-X4^'KRV%LT
M,F8[O4<XN;CT(5E$2]>(B0<.:^'/'W@O1OB+X.U'P5K\6ZUU"V:)SC)1L?*X
M]U;##W45_1W#/AG3K\`5%B(6Q.(M.+>\;?`O)/[7^)GY)F7&$Z7%494Y7HT_
M<?G=ZO[_`,C\PJZCX+?&+Q[\`/BKX>^-'POUN33O$/A;6K;5=%OHCS#<P2"2
M-B/XAD8*GA@2IX)JEX]\&ZQ\._%M_P"#=?AVW5C<-%)@<,`<AAZ@@@CV(K$^
ME?SO7H5<-6E2J*THMIKLUH_Q/UF$X58*47=/5?,_;;]IZ[\#_';PCX._;_\`
M@QI<-IX3^,=@][J>F6LFY=!\21'9JFG-W4"?,L>0NZ.4,`!7CIZ\5P__``0G
M_:#T3QY<^+/^"7GQ9UM+70_BRZ7_`,.=0O9`(M&\:0*1:L,\(MY'FTD/))$`
M&.2/0]>T+6/"^N7GAKQ#ITUG?Z?=26U]:3H5>"9&*NC`]"""#7]9>$_%G]NY
M#]4KRO6H63\X_9?Z/T/POC;)7E6:>TIQ]RIJO)]5]^OS/N#_`(-]_AE=^+?V
MTK_XA-;L;7PGX2N93+C@3W#I!&I],H9C_P``K]N:^'?^"%W[*=Y\`/V3V^)G
MB[36MM>^(MS'J<D<JX>+3T4K:(?JK23?2<#`Q7W%7X'XE9U3SSC#$5:3O"%H
M)]^7?Y7N?IO!N7RR_(::FK2G>37KM^%@HHHKX,^J"C`]***`$*J>JC\J7`/4
M444`%>+_`/!0#XN^-O@/^Q_X[^+WPVU&.VUS0M'$^G3S0+*B2&6-<E&!###'
M@U[17G'[5/P(M/VF_@#XF^!5UXB;2(_$FG_96U*.V\YH!O5]P0LH;[OJ.M=.
M!G0IX^C.NKP4HN772ZO\K7.;&1JSPE2-+XFG;UL?$'Q=_P""E7[1_A_]BG09
MO"FJ6$/QG@\3:[I7BX26$;1VJ:)'-/?S"(KM'[D6Q`QC,_';-_XP?MO_`![T
M[X^_#SX;']I2#P!H^O\`P*TSQ3J6JCX?C6FEU.::5'41)AD5@H(P=HV8QS7L
M/C+_`()4?#WQ;\8OBQ\7(?B#=VDGQ,\*W>D1:<U@)8=&GNX88KJ\B!<;Y)!`
MA8?+G)&<58\3?\$\OB#%\7O"GQK^$?[3,WA76?#'PLL_!"N?"4%\MS:P3-*9
M2LD@"L[,.,';MX/-?>4LSX-48QA3BFU-MN.TII-1^&:M!^ZKQ?5]3Y!X3B/7
MFDVERI)/=1=F]UK)+F>O4XOXG_&#]JIOB+^SK\"?A=^T_9BY^*.G^(KK5O',
MW@&)?M:VMM'=V[K92N/)^0F,KN'7)Z8K'^(/[7_[6?[.MY\8/@%\4/'FC>)/
M$WA7X2OXX\$^,].T%;,R0"86[Q7%KO>/<LC#:!U`).[(KUCXJ_L/?&7XG>)O
MA;\33^U7)9>.OAC%JZP>)E\%VTD>H-?QK$[-;F0)'MA78`-P.<\'K3M?^":=
MMK'@_P")<OQ-^.NL^*?'/Q0\.?V)J/C/4=.A0:?9`?+#;6L>U(XPP#%=W)4'
M.<D^?1QG#T*=+VKA))>\E3=^=UF^:_*O<]G;2^M[<O;HJ87.'4FZ?.F]FY:<
MOLTFK7?O.6W;N<7IW[4?[4G[07Q,^&G[-'P:\=Z3X5U34/@SIGC?Q[XVO-$6
M\D'V@1IY%M;LRQAFD<,2V0`W&-F#V_[4WQ[^)_[!_P"Q?K/BGXF_&"R\7^-+
MR]_L[PGJMWI$.G))=W'$"R1*Y0K$`\K,2`5C.<5-XK_X)W7*7?P_\=?!KXZ:
MEX+\>>`_!5OX7A\46FE174&JZ=%&J^5=6LC!74L"X`<%2W4D*1-+^P5XZ^(O
MQ3\"?$S]I_\`:('C^/P+-?75IHDGA""RL[J[G38DLD:R,I$2A2H8,=V3N`.T
M<]7$Y#/$4IQY51CK*'(^>4DV_BY7I*R25U9/8UC0SF-*<&G[25DI<WNQ5DKV
MONM6]-[]SQ3X>?\`!1'XN:U^Q)\<=5G^*7AS7OB+\)[F06GB?0%AEL=1M)74
MVEVB)F,@XEC(YQY8SR2*^U?@+XLUGQQ\%/"'C;Q'.LNH:SX7T^]O9$0*K2RV
MZ.Y`'`RS'@5X)\?_`/@E_P"#_BOX]\4>-?`?CT>";7QC\/6\+>(=&TK0HW@N
ME$PEBN=H=`LB%0.ARHQQDYEMOV>?VZ_@E\(9O"WPR_:MT_Q3>6>AVVE>&--U
MCP9;64-CME@C^TO*C,TGE0+*1&1\YQS6>:/A_'8=/"SC3G*:DU)-6O&*<4U'
MELI*32T23*R_^U\'5M7C*<5%JZ:=[2=G9N]VK:L^COB!JEYHG@K6-<TZ0)<6
M6EW$T#%<@.L98''?D#BOSG\0?\%`?VZM0_9F_9S\>?#&\T_6O%GCU?$EYXDT
MPZ7$HU>+2W:;R(P%_=LT$4B#9@EB*_16^\)ZAJ_@*7PEJVN&>XN=):SN]0,`
M4RNT91I=B\`DDMM'`Z=*^?\`X._\$Y-.^$MC\"[*W^*$][_PI&376MF?2EC_
M`+6_M*.1"&_>'R=GF9XW9QVK'(\;DV"A)XR"G+FNDU=-*E45GY.;A^?0Z,UP
M^9XJ<5AY.*:LVG:SYX._RCS''VO_``4<M/%?Q-T/XA^"]5%U\.KCX!:YXWU#
M3%A0W*7EC.@DA:09*N@\R-DZ;AGFM3]D:3]NC]H[P7X2_:9\:_M&Z+X?TGQ!
M-#JD?@+2O!L-Q`-+:0,(&NY)!+YLD7\8^ZS`X.,5I_#O_@ES\+OAO^U1XN_:
M"T3Q3,VA>+]`O]/O?`+V8^Q0&^,+7;Q/O^19#$28PH'SG!```L?!7]ASXY?L
MZS:5X*^%'[9^J0_#C1]32:V\(:QX0M;RY2T\WS'LDOBZLL;`LH8QEE#<<@&N
MW%XKAV.%E3P;C&34=9P<M/><HKW96DKQ3GIS6TDCCHT,X6(4\4G*-WI&25OA
M2>ZO'1NVMK[,^H:^5?\`@K+^V4G['O[+FH:EX;U,0>+?%._2?"JH_P`\,C)^
M]NP.PA3)#=/,:,'[U>Z_"[P5X^\&WOB2Y\<_%FY\3QZOK\U[HD%SIT5O_9%H
MP&RR4Q\RJA!(D?YCNYZ5^67_``73_9L_;.\=?&O_`(71+X*N-<^'>D:6EMH;
MZ`'N#ID8&^:2YB`W(SR9)D`*;4C!;Y:7`^5Y;FG%-"AC:L8TD^9W=E*VO*KV
MW>COTN;\39AC,'DDZF'IOG>G?EOHWI?IV/S=9Y9':6:0N[L69B<DD]Z*-P+%
M1U4X(/:BO[>IRC*/N['\^]=3YN_;Q^!%YXIBLOBCX2TB6XO8F6UU6&VC+-)&
M?]7)@<G!^4GT*^E?+H^&OCW'_(A:Q_X*Y?\`"OTSJQI6E:KKNI0Z-HFG7%Y=
MW,@CMK6UB:225ST557))/H*_(N*_"G+<]S2>8_6'1YM9+E35UUNVK7\S[S)N
M.L9EF`AA'1]IRZ)W:=NBV>Q^:7AWPM\5_"FM6GB3P]X9\06.H6%U%=6%[9V,
M\<MO/&X>.1&`RK*P#`CD$"OZ+?V!OV6-!_X+!W?P]_X*!^-M.32+&[LS;_&G
MPU);-`]SXFL#&DAB3:`(+Q#%<,5SM#.N=Y&V']@O_@AG\6/C!J-G\1/VK;:\
M\(^&$=94\/9"ZGJ*\':X_P"75#T.[]YU`5>&K]@?AS\./!?PG\%Z?\//A]X<
ML])T72;9;?3M.LH0D<"#L!W)/))Y)R3DDU^(YM5P7!..E3R+'.K4DG"<E%**
M3T:3N[M;IK1-)JY]]@XXCB;#1EF6%]G"+4HKF]YM=U967YFY9V5M8VZ6EK`D
M<42!(XT4!44#```Z`#BI:**_/=SZY*P4444`%%%%`!1110`4FU?0444`+@>E
M)M7T%%%`!M7.=HSZXHVJ.BC\J**5D`;5_NC\J7`]!113`0JIZ@&AD1AAE!^H
MHHH`6C`]***`#`'0"DVK_='Y444`&Q.NT?E041@0R`@]01110%D>#_&[_@FY
M^Q9^T3=3:K\3/@#HDNH3L6EU72XFL+EV/\3R6[(TA_WRU>":]_P;S?L,:M<"
M?3_$_P`0M*0$_N+'7K9EYQ_SVM9&X^O>BBO8P/%W$V6TE3PV+J0BNBG*WW7/
M(Q&19-BI.=6A&3[V1>\(?\&_O[!?AB=)]8E\9^(51LF+5]?1%8>A^S10D_GF
MOI3X%?L>?LT?LW6^SX)_!?0=`EV;'O;:RWW4B^C3R;I6'L6-%%8XWB;B#-XJ
M.,Q4YKLY-K[KV_`O"Y)E."G^XH1B^Z2O]YZCM7^Z/RI<#THHKS3U`HHHH`__
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
